JPS6256134B2 - - Google Patents
Info
- Publication number
- JPS6256134B2 JPS6256134B2 JP62000347A JP34787A JPS6256134B2 JP S6256134 B2 JPS6256134 B2 JP S6256134B2 JP 62000347 A JP62000347 A JP 62000347A JP 34787 A JP34787 A JP 34787A JP S6256134 B2 JPS6256134 B2 JP S6256134B2
- Authority
- JP
- Japan
- Prior art keywords
- gangliosides
- day
- patients
- group
- ganglioside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000002270 gangliosides Chemical class 0.000 claims description 125
- 241001465754 Metazoa Species 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000008055 phosphate buffer solution Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 239000012046 mixed solvent Substances 0.000 claims 2
- XSQZVVZUBCLKSB-UHFFFAOYSA-L C(C)O.[OH-].[Ba+2].[OH-] Chemical compound C(C)O.[OH-].[Ba+2].[OH-] XSQZVVZUBCLKSB-UHFFFAOYSA-L 0.000 claims 1
- 239000003929 acidic solution Substances 0.000 claims 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000005342 ion exchange Methods 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 description 36
- 241000700159 Rattus Species 0.000 description 34
- 238000011282 treatment Methods 0.000 description 31
- 238000012360 testing method Methods 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 26
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 210000005036 nerve Anatomy 0.000 description 22
- 230000006872 improvement Effects 0.000 description 19
- 238000011084 recovery Methods 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 230000037396 body weight Effects 0.000 description 16
- 210000003205 muscle Anatomy 0.000 description 16
- 230000003247 decreasing effect Effects 0.000 description 14
- 239000008363 phosphate buffer Substances 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 208000021017 Weight Gain Diseases 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 235000019786 weight gain Nutrition 0.000 description 12
- 230000005856 abnormality Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 208000033808 peripheral neuropathy Diseases 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000010254 subcutaneous injection Methods 0.000 description 10
- 239000007929 subcutaneous injection Substances 0.000 description 10
- 230000004584 weight gain Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 235000021050 feed intake Nutrition 0.000 description 9
- 238000010255 intramuscular injection Methods 0.000 description 9
- 239000007927 intramuscular injection Substances 0.000 description 9
- 210000001428 peripheral nervous system Anatomy 0.000 description 9
- 230000035935 pregnancy Effects 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 206010029240 Neuritis Diseases 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 230000008719 thickening Effects 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 206010036105 Polyneuropathy Diseases 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000036244 malformation Effects 0.000 description 7
- 201000001119 neuropathy Diseases 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 208000035824 paresthesia Diseases 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 201000004384 Alopecia Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 230000003676 hair loss Effects 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000007823 neuropathy Effects 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 208000019629 polyneuritis Diseases 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 description 5
- 241000700198 Cavia Species 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 230000036783 anaphylactic response Effects 0.000 description 5
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 208000024963 hair loss Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000002751 lymph Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 210000000578 peripheral nerve Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000005062 synaptic transmission Effects 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- 230000009278 visceral effect Effects 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010024769 Local reaction Diseases 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 206010035039 Piloerection Diseases 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000009533 lab test Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 206010030875 ophthalmoplegia Diseases 0.000 description 4
- 210000001328 optic nerve Anatomy 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000005371 pilomotor reflex Effects 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 210000003497 sciatic nerve Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- 238000005353 urine analysis Methods 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 3
- 206010011878 Deafness Diseases 0.000 description 3
- 208000004929 Facial Paralysis Diseases 0.000 description 3
- 206010017577 Gait disturbance Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 206010028400 Mutagenic effect Diseases 0.000 description 3
- 208000003435 Optic Neuritis Diseases 0.000 description 3
- 241000283977 Oryctolagus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000004159 blood analysis Methods 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000003210 demyelinating effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000010370 hearing loss Effects 0.000 description 3
- 231100000888 hearing loss Toxicity 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 230000036540 impulse transmission Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 231100000243 mutagenic effect Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 238000002577 ophthalmoscopy Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- 108091005508 Acid proteases Proteins 0.000 description 2
- 208000003130 Alcoholic Neuropathy Diseases 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 201000009487 Amblyopia Diseases 0.000 description 2
- 241001471112 Artocarpus tamaran Species 0.000 description 2
- 208000026389 Binocular eye movement disease Diseases 0.000 description 2
- 208000009132 Catalepsy Diseases 0.000 description 2
- 241000252095 Congridae Species 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 241000722985 Fidia Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000019430 Motor disease Diseases 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 206010039729 Scotoma Diseases 0.000 description 2
- 208000020764 Sensation disease Diseases 0.000 description 2
- 208000004350 Strabismus Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047853 Waxy flexibility Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000860 cochlear nerve Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 210000000256 facial nerve Anatomy 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002421 ganglioside group Chemical group 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 208000028780 ocular motility disease Diseases 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 231100000161 signs of toxicity Toxicity 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 231100000456 subacute toxicity Toxicity 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010001912 Amblyopia strabismic Diseases 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 241000606643 Anaplasma centrale Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010014523 Embolism and thrombosis Diseases 0.000 description 1
- 208000009701 Embryo Loss Diseases 0.000 description 1
- 101710087274 Endothelial lipase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 208000037397 Fetal Weight Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 208000035223 Gestational Weight Gain Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 244000158996 Hedysarum boreale Species 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 241001124320 Leonis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000997826 Melanocetus johnsonii Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000223503 Platysma Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 101000941277 Rattus norvegicus Endothelial lipase Proteins 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000005439 Sleep paralysis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- 101100162976 Sus scrofa APOR gene Proteins 0.000 description 1
- 241000897276 Termes Species 0.000 description 1
- 206010068872 Toe walking Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000020701 alcoholic polyneuropathy Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000604 anti-edema agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000012076 audiometry Methods 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037185 brain physiology Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- DXHPZXWIPWDXHJ-UHFFFAOYSA-N carbon monosulfide Chemical compound [S+]#[C-] DXHPZXWIPWDXHJ-UHFFFAOYSA-N 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 231100000147 cell transformation assay Toxicity 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 231100001048 fetal toxicity Toxicity 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 208000018904 loss of tendon reflex Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 230000005813 organ abnormality Effects 0.000 description 1
- 206010033103 otosclerosis Diseases 0.000 description 1
- 231100000199 ototoxic Toxicity 0.000 description 1
- 230000002970 ototoxic effect Effects 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 150000003019 phosphosphingolipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 208000000813 polyradiculoneuropathy Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 206010061928 radiculitis Diseases 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000036981 sensorimotor activity Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- 201000009485 suppression amblyopia Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Extraction Or Liquid Replacement (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT26323/75A IT1046051B (it) | 1975-08-13 | 1975-08-13 | Nuova applicazione terapeutica dei gangliosidi e procedimento per la loro estrazione |
| IT26323A/75 | 1975-08-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62187412A JPS62187412A (ja) | 1987-08-15 |
| JPS6256134B2 true JPS6256134B2 (fr) | 1987-11-24 |
Family
ID=11219226
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51097402A Granted JPS5234912A (en) | 1975-08-13 | 1976-08-13 | Extraction of ganglioside and application of same to new medicines |
| JP62000347A Granted JPS62187412A (ja) | 1975-08-13 | 1987-01-05 | ガングリオシツドの抽出法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51097402A Granted JPS5234912A (en) | 1975-08-13 | 1976-08-13 | Extraction of ganglioside and application of same to new medicines |
Country Status (7)
| Country | Link |
|---|---|
| JP (2) | JPS5234912A (fr) |
| AT (1) | AT352296B (fr) |
| BE (1) | BE843695A (fr) |
| DE (1) | DE2549680A1 (fr) |
| ES (1) | ES441233A1 (fr) |
| FR (1) | FR2320760A1 (fr) |
| IT (1) | IT1046051B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2451194A1 (fr) * | 1979-03-16 | 1980-10-10 | Merieux Inst | Nouveau medicament a base de ganglioside notamment pour le traitement du cholera, et compositions pharmaceutiques le contenant |
| US4347244A (en) * | 1979-03-16 | 1982-08-31 | Societe Anonyme Dite: Institut Merieux | Ganglioside containing compositions for treating diarrhea |
| CA1168980A (fr) * | 1980-04-17 | 1984-06-12 | Rolf Schafer | Compositions cicatrisantes |
| EP0058665B1 (fr) * | 1980-05-09 | 1986-02-26 | LEFFLER, Hakon | Derives d'hydrate de carbone pour inhiber l'adherence bacterienne |
| ATE42301T1 (de) * | 1983-05-27 | 1989-05-15 | Shanksville Corp N V | Abschaffung von transplantatabstossreaktion in der organtransplantation. |
| JPS59222424A (ja) * | 1983-06-01 | 1984-12-14 | Katsutaka Nagai | 神経障害疾患治療剤 |
| IT1177863B (it) * | 1984-07-03 | 1987-08-26 | Fidia Farmaceutici | Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche |
| JPH01228997A (ja) * | 1988-03-10 | 1989-09-12 | Mect Corp | シアロシルグリセライド類及びその製造方法 |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| AR241751A1 (es) * | 1989-07-12 | 1992-12-30 | Beta Lab Sa | Procedimiento para obtener mezclas de gangliosidos para el tratamiento de enfermedades psico-organicas y del caracter. |
| IT1232176B (it) | 1989-07-27 | 1992-01-25 | Fidia Farmaceutici | Derivati di-lisogangliosidi |
| IT1238346B (it) * | 1989-11-14 | 1993-07-13 | Gangliosidi modificati e loro derivati funzionali. | |
| JPH0580009A (ja) * | 1991-09-20 | 1993-03-30 | Kubota Corp | 炭酸濃度測定方法 |
| JPH0580010A (ja) * | 1991-09-25 | 1993-03-30 | Kubota Corp | 気体中の炭酸ガス濃度測定方法 |
| JP4005115B1 (ja) * | 2007-02-08 | 2007-11-07 | 日本臓器製薬株式会社 | 疼痛疾患治療剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT127981B (de) * | 1929-06-07 | 1932-04-25 | Schering Kahlbaum Ag | Verfahren zur Herstellung eines die zentralen Tätigkeiten fördernden und regulierenden Reizstoffes. |
| CH193176A (de) * | 1936-12-08 | 1937-09-30 | Richter Arthur | Verfahren zur Gewinnung eines Wirkstoffes aus Säugetiergehirn. |
| US3436413A (en) * | 1965-12-21 | 1969-04-01 | Canada Packers Ltd | Process for the isolation of phosphatidyl serine |
-
1975
- 1975-08-13 IT IT26323/75A patent/IT1046051B/it active Protection Beyond IP Right Term
- 1975-09-24 ES ES441233A patent/ES441233A1/es not_active Expired
- 1975-11-05 DE DE19752549680 patent/DE2549680A1/de active Granted
- 1975-12-30 FR FR7540170A patent/FR2320760A1/fr active Granted
-
1976
- 1976-07-01 BE BE168566A patent/BE843695A/fr not_active IP Right Cessation
- 1976-08-13 AT AT606976A patent/AT352296B/de not_active IP Right Cessation
- 1976-08-13 JP JP51097402A patent/JPS5234912A/ja active Granted
-
1987
- 1987-01-05 JP JP62000347A patent/JPS62187412A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| BE843695A (fr) | 1976-11-03 |
| JPS62187412A (ja) | 1987-08-15 |
| ATA606976A (de) | 1979-02-15 |
| JPS6250450B2 (fr) | 1987-10-24 |
| ES441233A1 (es) | 1977-03-16 |
| FR2320760B1 (fr) | 1978-11-17 |
| FR2320760A1 (fr) | 1977-03-11 |
| IT1046051B (it) | 1980-06-30 |
| AT352296B (de) | 1979-09-10 |
| DE2549680C2 (fr) | 1988-05-11 |
| DE2549680A1 (de) | 1977-02-24 |
| JPS5234912A (en) | 1977-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Egger et al. | Mitochondrial cytopathy. A multisystem disorder with ragged red fibres on muscle biopsy. | |
| Waldmann et al. | The association of polycythemia with a cerebellar hemangioblastoma: The production of an erythropoiesis stimulating factor by the tumor | |
| JP2539665B2 (ja) | 神経疾患治療剤 | |
| JPS6256134B2 (fr) | ||
| US6165515A (en) | Method for treatment of osteoporosis | |
| EP0140998B1 (fr) | Préparations ophtalmiques | |
| Anderson et al. | Symptomatic cataplexy. | |
| McEACHERN | The thymus in relation to myasthenia gravis | |
| JP2539669B2 (ja) | 糖尿病性神経障害治療剤 | |
| KNUTSON et al. | The central nervous system in uremia: a clinicopathologic study | |
| CZ181193A3 (en) | Pharmaceutical preparation in the form of a solution for local administration in eye, the use and preparation method thereof | |
| Hartman | Studies on the function and clinical use of cortin | |
| US6365192B1 (en) | Bioactivating substance | |
| STRAUSS et al. | Intramuscular Use of Liver Extract: Maximal Responses of Reticulocytes from Daily Intramuscular Injection of Extract Derived from Ten Grams of Liver: Preliminary Communication | |
| Inagaki et al. | Relief of chronic burning pain in Fabry disease with neurotropin | |
| Hoefnagel et al. | Addison's disease and diffuse cerebral sclerosis | |
| GB2092001A (en) | Pharmaceutical preparations comprising sodium fructose-1, 6-diphosphate for treatment of burn patients | |
| Paine et al. | Atypical Variants of the ‘Ataxia Telangiectasia’Syndrome: Report of Two Cases, Including One with Apparent Dominant Inheritance | |
| Shibasaki et al. | Carbamazepine for painful crises in Fabry's disease | |
| EP0129093B1 (fr) | Utilisation du L-fucose dans la préparation d'un médicament pour inhalations et procédé de préparation du L-fucose | |
| RU2129427C1 (ru) | Способ лечения заболеваний центральной нервной системы | |
| Horne et al. | Effect of Para-Aminosalicylic Acid (PAS) Alone and in Association with Streptomycin on Experimental Ocular Tuberculosis | |
| WHITEHEAD et al. | A Case of Diabetes Insipidus Occurring as a Sequel to Epidemic Encephalitis | |
| Friedman | Pharmacology—Lithium’s Effects on Cyclic AMP, Membrane Transport, and Cholinergic Mechanisms | |
| JPH01230520A (ja) | 新規生理活性物質 |